Navigation Links
Steven Leventer Joins PharmaNet Development Group as Vice President, Clinical Research Neuroscience

PRINCETON, N.J., Jan. 25 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, announced today that Steven Leventer, Ph.D. has been appointed Vice President, Clinical Research Neuroscience.

"We are very pleased to have Steve join PharmaNet Development Group," commented Dalvir Gill, Chief Operating Officer, Late Stage Development. "Steve is a recognized expert in the fields of clinical trial design and clinical development planning. His combination of neuroscience expertise and dedication to efficiency and quality provides the right complement to our existing organization."

Dr. Leventer has over twenty years of experience in all phases of drug development. He has spent most of his career leading clinical teams at large global pharmaceutical and contract research organizations in the development of therapeutics for Alzheimer's disease, schizophrenia, depression and other central nervous system diseases. He was trained as a neurochemist and has had post-doctoral fellowships and faculty appointments at the University of Texas, Western Psychiatric Institute and Clinic, and Loyola University Stritch School of Medicine.  

About PharmaNet Development Group, Inc.

PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2,300 employees and more than 43 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit our website at  

    Contact: Anne-Marie Hess
    Phone: (609) 951-6842

SOURCE PharmaNet Development Group, Inc.



SOURCE PharmaNet Development Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. D-M-S Holdings, Inc. Announces the Filing of a Lawsuit Against Veridian Healthcare, LLC, Steven M. Bisulca and Michael Mazza
2. Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Successor
3. New Life Agency, Inc. Joins Forces With The Diamond Institute and Walgreens Specialty Pharmacy to Introduce the Nations First In Vitro Fertilization Insurance Program
4. CooperVision Adds Global Professional Relations Role; Richard Clompus Joins Company as Vice President
5. Professor Riccardo Lencioni Joins Delcath Systems Scientific Advisory Board
6. Royalty Pharma Announces that Alexander von Perfall Joins Management Team
7. Howard Goldstein Joins Microchip Biotechnologies, Inc. as Executive Vice President
8. Scott Glenn Joins Exagen Diagnostics as Chairman and CEO
9. PFC Pharma Joins DATATRAKs CRO Connect Program
10. William Cork Joins Fenwal as Chief Technology Officer
11. Jeffrey Trotter Joins Pharmanet Development Group as Executive Vice President, Phase IV Development
Post Your Comments:
(Date:12/1/2015)... Russia has always been a ... new drugs registered in Europe in 2015 were ... Russia has always been a country of choice ... in Europe in 2015 were tested in phase ... Russia has always been a country of choice for global ...
(Date:12/1/2015)... , Dec. 1, 2015 CytRx Corporation (NASDAQ: ... specializing in oncology, today announced that it has reached ... pivotal global Phase 3 clinical trial of aldoxorubicin in ... originally estimated to be completed in Q1 2016. The Phase ... under a Special Protocol Assessment from the FDA at ...
(Date:12/1/2015)... 1, 2015  The migration to value-based care ... care plans that help patients stay healthy and ... be digitally enabled, incorporate care guidelines and be ... They will also allow all stakeholders to collaborate ... is optimal. That is the vision, however, research ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... 01, 2015 , ... Growth in medical payments per workers’ compensation claim in ... hospital and nonhospital care, according to a recent study by the Workers Compensation Research ... , found medical payments per claim with more than seven days of lost time ...
(Date:12/1/2015)... ... December 01, 2015 , ... CloudLIMS today announced that ... Business Awards under the New Products and Services category for its innovative product ... management software that helps labs organize data and track samples with storage ...
(Date:12/1/2015)... New York, NY (PRWEB) , ... December 01, ... ... cause of non-traumatic limb amputations in the United States. Podiatrists are well aware ... (failure to adopt therapeutic behaviors) are often catastrophic contributors to diseases of the ...
(Date:12/1/2015)... ... December 01, 2015 , ... For the millions of ... Hollister Incorporated has launched the VaPro Plus Pocket™ touch free hydrophilic intermittent catheter. ... touch free catheter portfolio,” said Michael Gresavage, Vice President North America. "We designed ...
(Date:12/1/2015)... ... 01, 2015 , ... Next IT Healthcare, the leader in ... this year’s Fierce Innovation Awards: Healthcare Edition, an awards program from the publisher ... in the category of Digital Solutions for its innovative, industry-leading product, Alme Health ...
Breaking Medicine News(10 mins):